Details for Patent: 12,102,638
✉ Email this page to a colleague
Which drugs does patent 12,102,638 protect, and when does it expire?
Patent 12,102,638 protects GEMTESA and is included in one NDA.
This patent has twenty-three patent family members in fourteen countries.
Summary for Patent: 12,102,638
| Title: | Use of vibegron to treat overactive bladder |
| Abstract: | The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day. The present disclosure is also directed to a pharmaceutical unit dosage composition comprising from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron for oral administration. |
| Inventor(s): | Stephen C. PISCITELLI, Paul Mudd |
| Assignee: | Sumitomo Pharma Co Ltd |
| Application Number: | US16/620,179 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 12,102,638
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,102,638
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018282104 | ⤷ Start Trial | |||
| Australia | 2024204591 | ⤷ Start Trial | |||
| Brazil | 112019025636 | ⤷ Start Trial | |||
| Canada | 3064989 | ⤷ Start Trial | |||
| Chile | 2019003533 | ⤷ Start Trial | |||
| China | 110869022 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
